Session Information
Date: Monday, October 27, 2025
Title: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster
Session Type: Poster Session B
Session Time: 10:30AM-12:30PM
Background/Purpose: Experimental and clinical studies suggest that fascial structures play a critical role in the pathogenesis and pain mechanisms of myofascial pain syndrome (MTrP). It is proposed that incorporating fascial structures into treatment may enhance therapeutic outcomes. However, no high-quality randomized controlled trials have been conducted to evaluate this hypothesis. This study aims to assess whether including fascial structures in treatment provides additional benefits compared to conventional intramuscular MTrP injections.
Methods: This triple-blind, randomized, parallel-group, single-center prospective study included seventy-six patients aged 18–65 years diagnosed with active MTrP. In the myo-fascial injection group, injections targeted intermuscular fascia, deep fascia, and superficial fascia in addition to MTrP. In the myo-injection group, only intramuscular injections were performed. Pain intensity, pressure pain threshold, and functional status were assessed before treatment and at 30 minutes, 3 days, and 1 week after treatment.
Results: A significant reduction in pain intensity was observed in both groups at all post-treatment time points compared to baseline. The pressure pain threshold increased after treatment but decreased after the third day. Functional status improved in both groups by the third day, and this improvement continued through the first week. However, no significant differences were found between the groups at any time point regarding any measured outcome.
Conclusion: The injection method targeting fascial structures did not provide a significant advantage over the conventional intramuscular trigger point injection method. Further studies are needed to evaluate the long-term effects of including fascial structures in treatment.
Primary and Secondary Outcome Measures and Between Group Comparisons
To cite this abstract in AMA style:
yildiz s, ince b, candal H. Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/myo-vs-myo-fascial-injection-for-myofascial-trigger-points-is-there-really-a-difference-a-randomized-controlled-trial/. Accessed .« Back to ACR Convergence 2025
ACR Meeting Abstracts - https://acrabstracts.org/abstract/myo-vs-myo-fascial-injection-for-myofascial-trigger-points-is-there-really-a-difference-a-randomized-controlled-trial/